Premium
Fertility Drugs and Gynecologic Cancer
Author(s) -
KANAKAS NIKOS,
MANTZAVINOS THEMIS
Publication year - 2006
Publication title -
annals of the new york academy of sciences
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.712
H-Index - 248
eISSN - 1749-6632
pISSN - 0077-8923
DOI - 10.1196/annals.1365.022
Subject(s) - fertility , endometrial cancer , ovulation , ovulation induction , medicine , cancer , gynecology , endometrium , in vitro fertilisation , breast cancer , ovarian cancer , hormone , ovary , physiology , obstetrics , biology , pregnancy , population , environmental health , genetics
Fertility drugs (FD) are spreading worldwide fast and therefore many studies have reviewed the possible association between the use of these drugs and cancer. Since the drugs used for ovulation induction during in vitro fertilization (IVF) like hCG, hMG, rFSH increase the levels of gonadal hormones, concerns have grown regarding the risk of developing cancer in breast, ovary, endometrium, and other target organs. In this review, we discuss a number of different studies published in recent years that show no association between the use of these drugs and most cancers.